コンテンツへスキップ
Merck
  • Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent.

Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent.

International journal of clinical pharmacy (2012-08-10)
Maryam Karimi Khaledi, Katie J Suda, Chasity M Shelton
要旨

The objective of this case report is to report the development of tardive dyskinesia in an African-American adolescent male after short-term treatment with metoclopramide 10 mg orally three times daily secondary to delayed gastric emptying. The patient developed symptoms of tardive dyskinesia after 2 days of therapy with metoclopramide. Metoclopramide was discontinued and diphenhydramine 50 mg was initially administered intravenously followed with 25 mg orally every 4 hours as needed. While there are case reports of drug-induced tardive dyskinesia after intravenous administration of metoclopramide, this is to our knowledge the first report of tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent. Awareness of the risk of development of this adverse effect even with short-term treatment with metoclopramide and in younger patients is important.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ジフェンヒドラミン 塩酸塩, ≥98% (HPLC)
Supelco
ジフェンヒドラミン 塩酸塩, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
ジフェンヒドラミン 塩酸塩, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
ジフェンヒドラミン 塩酸塩, European Pharmacopoeia (EP) Reference Standard
Supelco
メトクロプラミド, VETRANAL®, analytical standard